Boston, Mass and Copenhagen, Demark – PerkinElmer Inc. (NYSE: PKI), a leading provider of drug discovery, life science research, and analytical solutions, today announced plans to collaborate with BioImage to develop cell-based assays on the PerkinElmer EnVision™ HTS multilabel plate reader platform. The commercial terms of the collaboration were not disclosed. Based in Denmark, BioImage is a leader in using protein translocation based technology to identify novel therapeutics.
The collaboration combines the BioImage assay technology with the PerkinElmer EnVision detection platform to develop a series of cell based screening methods. BioImage has developed a suite of assay technologies for measuring protein-protein interactions in living cells using PerkinElmer’s EnVision platform. The EnVision provides extremely sensitive fluorometric detection at high speeds, making it the ideal detection platform for the BioImage assays. This powerful combination enables customers to perform robust cell based identification of inhibitors of protein/protein interactions at throughput levels previously not available.
“As a leader in high-content screening and cell-based assay development, BioImage has an excellent skill base and holds a strong IP position in this space,” said Peter Coggins, Ph.D., president, PerkinElmer Life and Analytical Sciences.
“This agreement provides a logical avenue for us to commercialize some of our technologies and collaborate with the leading provider of plate readers in the HTS market,” said Dr. Patrik Dahlén, CEO of BioImage. “We are actively out-licensing our IP estate and marketing our assay development services, and are confident that the assays validated on the EnVision platform will be of great interest to many bio-pharmaceutical companies.”
For more information, contact:
PerkinElmer Life and Analytical Sciences
549 Albany Street, Boston, MA, 02118, USA
Telephone: (800) 762-4000 (U.S. Only) or +1 (617) 482-9595
Fax: +1 (617) 482-1380